Table 1 Characteristics of the included studies
Author | County | Design | Age (years) | Subjects | Follow-up time | Vaccinated | Dengue vaccine* | Control | Dengue Control** |
|---|---|---|---|---|---|---|---|---|---|
Villar et al. [10] | Colombia, Brazil, Mexico, Honduras and Puerto Rico. | ECR phase III | 9 to 16 | 20,869 | 25 months after the 1st dose | 13,920 | 280 | 6949 | 388 |
Capeding et al. [11] | Indonesia, Malaysia, Philippines, Thailand and Vietnam. | ECR phase III | 2 to 14 | 10,272 | 25 months after the 1st dose | 6848 | 286 | 3424 | 309 |
Dayan et al. [12] | Brazil | ECR phase II | 9 to 16 | 150 | 6 months after the 3rd dose | 100 | 31 | 50 | 15 |
Villar et al. [13] | Colombia, Mexico, Honduras and Puerto Rico. | ECR phase II | 9 to 16 | 600 | 6 months after the 3rd dose | 401 | 43 | 199 | 29 |
Sabchareon et al. [16] | Thailand | ECR phase IIb | 4 to 11 | 4002 | 25 months after the 1st dose | 2669 | 76 | 1333 | 58 |
Tran et al. [14] | Vietnam | ECR phase II | 2 to 45 | 180 | 6 months after the 3rd dose | 120 | 4 | 60 | 3 |
Lanata et al. [15] | Peru | ECR phase II | 2 to 11 | 298 | 1 month after the 3rd dose | 199 | 1 | 99 | 3 |